Completed PHASE4 INTERVENTIONAL 2-arm NCT00940862

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

Pilot Study on the Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

Sponsor: Abbott

Conditions Coronary Atherosclerosis Psoriasis Vascular Inflammation

Interventions Topical treatment UVB Phototherapy adalimumab

Updated 5 times since 2017 Last updated: Oct 27, 2011 Started: Jul 31, 2009 Primary completion: Jun 30, 2011 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00940862, this PHASE4 trial focuses on Coronary Atherosclerosis and Psoriasis and remains completed. Sponsored by Abbott, it has been updated 5 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Innovaderm Research Inc.
Montreal Heart Institute

Data source: Innovaderm Research Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada